The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

As per The Business Research Company’s Convalescent Plasma Therapy Global Market Report 2024, the convalescent plasma therapy market is expected to show significant growth in the forecast period.

The convalescent plasma therapy market has experienced rapid growth, surging from $0.05 billion in 2023 to $0.05 billion in 2024 at a compound annual growth rate (CAGR) of 11.8%. The historic period’s growth is attributed to pandemics and infectious disease outbreaks, immunotherapy research, emergency use authorization (EUA), patient availability, and heightened clinician and public awareness.

Anticipating Rapid Growth Ahead
The convalescent plasma therapy market is poised for further rapid growth in the coming years, reaching $0.08 billion in 2028, with a projected CAGR of 12.8%. This growth is driven by factors such as evolving pathogens, developments in immunotherapies, regulatory frameworks, global preparedness, and public health initiatives. Key trends in the forecast period include standardized collection and processing, targeted plasma components, personalized treatment approaches, the integration of telemedicine and remote monitoring, and extensive research into long-term effects.

Efficacy and Safety: Cornerstones of Market Growth

Trials Validate Efficacy and Safety
The efficacy and safety demonstrated during clinical trials for Convalescent Plasma Therapy (CPT) in COVID-19 patients play a pivotal role in propelling market growth. Historically, CPT has been of interest for treating infectious diseases like SARS-1, MERS, and the 2009 H1N1 outbreak. According to a systematic review and meta-analysis published in JAMA Network Open, convalescent plasma transfusion was associated with a mortality benefit in immunocompromised COVID-19 patients. The proven safety and efficacy in treating COVID-19 patients will undoubtedly boost the global convalescent plasma therapy market.

Contributions from Major Companies
Leading companies contributing to the growth of the convalescent plasma therapy market include Bio Farma, Hilton Pharma Ltd., Biotest AG, BPL Ltd., LFB SA, Octapharma AG, CSL Behring LLC, Takeda Pharmaceutical Company Ltd., and many more. These entities play a crucial role in advancing research, manufacturing, and ensuring the availability of convalescent plasma therapy.

View More On The Convalescent Plasma Therapy Market Report 2024 – https://www.thebusinessresearchcompany.com/report/convalescent-plasma-therapy-global-market-report

Antibody-Based Therapies: Catalysts for Market Uplift

Innovation with Antibody-Based Immunotherapy
The development of antibody-based immunotherapy represents a significant opportunity for the convalescent plasma therapy market. This therapeutic approach leverages antibodies produced against COVID-19 by donors to enhance the immunity of recipients. Companies are actively engaged in trials, collaborations, and investments in antibody-based COVID-19 therapies. In August 2023, Regeneron Pharmaceuticals Inc. collaborated with the Biomedical Advanced Research and Development Authority (BARDA) to advance the clinical development of next-generation COVID-19 monoclonal antibody therapy. This collaboration, part of Project NextGen by the U.S. Department of Health and Human Services, is expected to drive the market growth as convalescent plasma therapy relies on antibodies.

Segmentation for Precision

The convalescent plasma therapy market is segmented based on antibody type, application, and end-users:

1. Antibody Type:
   • IgM
   • IgG
   • IgA
2. Application:
   • Prophylaxis
   • Treatment
3. End-Users:
   • Hospitals & Clinics
   • Laboratories & Research Institutes

Regional Dynamics: North America Takes the Lead
In 2023, North America emerged as the largest region in the convalescent plasma therapy market. This regional dominance reflects the significant contributions, research advancements, and awareness campaigns conducted in the fight against infectious diseases.

In Conclusion
As the convalescent plasma therapy market continues to evolve, the emphasis on efficacy, safety, and innovative antibody-based therapies is set to drive substantial growth. With major companies at the forefront of research and development, the market’s trajectory is closely tied to global preparedness, regulatory frameworks, and a steadfast commitment to public health initiatives. Stakeholders in the healthcare sector must stay informed about emerging trends and advancements to contribute effectively to the battle against infectious diseases.

Request A Sample Of The Global Convalescent Plasma Therapy Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=3233&type=smp